SynAct is developing a new class of drug candidates targeting acute deterioration in chronic inflammatory diseases, with the primary aim of stimulating the natural healing mechanisms. The candidate drug AP1189 which is being developed for the treatment of psoriatic arthritis, is on the way to the clinical phase. In connection with this, SynAct has signed up one of Europe’s most experienced experts in clinical pharmacology, Dr. Thierry Duvauchelle, for the role of CMO in the company.
SynAct’s Chief Scientific Officer Thomas Jonassen comments:
“It has been a priority for the company to establish core competences for early clinical development. We have had very constructive initial cooperation with Dr. Duvauchelle, who has more than 25 years of experience in early clinical development. As CMO, Dr. Duvauchelle bring valuable expertise to the company to ensure that we can carry out our Phase I programme with the utmost safety and to the highest standards”.
Dr. Duvauchelle has been Head of Paris’s largest Phase I clinic, Aster-Cephac, for many years and has held the position of Corporate VP in SGS, responsible for their Clinical Phase I clinics in France and Belgium.
For further information about SynAct Pharma AB, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Telephone: +45 28 44 75 67
E-mail: [email protected]
Thomas Jonassen
CSO, SynAct Pharma AB
Telephone: +45 40 15 66 69
E-mail: [email protected]
This is information that SynAct Pharma AB is obliged to disclose under the EU’s market abuse regulation. The information was submitted by the above contact person for publication on 28 November 2016.
SynAct Pharma AB, Company registration number 559058-4826, is a biotech company that conducts research and development in inflammatory diseases via the wholly owned Danish subsidiary, SynAct Pharma ApS. The company has a platform technology based on a new class of drug candidate targeting acute deterioration in chronic inflammatory diseases, with the primary purpose of stimulating natural healing mechanisms. SynAct Pharma’s main focus is on the development of the candidate drug AP1189, which strengthens the body’s own cells and fights flares in inflammation by accelerating recovery and thereby reducing the risk of chronic inflammation deterioration.